TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07560449: A Multicenter, Open-Label Phase II Study to Evaluate QLS4131 Combination Therapy in the Treatment of Malignant Plasma Cell Neoplasms

Sponsor: Qilu Pharmaceutical Co., Ltd. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 162 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT07560449 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07560449 Rescue Dossier →